Research
Hormonal
Adiponectin levels are inversely correlated with visceral adipose tissue mass and obesity, and low levels are associated with insulin resistance, hypertension, and cardiovascular disease, while high levels may have protective anti-atherogenic effects.
Maintaining healthy adiponectin levels, often associated with lower body fat and physical activity, may protect against cardiovascular disease and insulin resistance. Strategies that improve insulin sensitivity may help maintain higher adiponectin levels.
GoodSupportsHIGH confidence
Adiponectin is the only adipokine that shows a negative correlation with visceral adipose tissue mass... Adiponectin in blood vessel walls inhibits monocyte adhesion to endothelial cells... Moreover, it inhibits smooth muscle cell proliferation, enhances nitrogen oxide synthesis and stimulates angiogenesis.
Why this rating
Supported by multiple studies cited in the review showing correlations with metabolic markers and cardiovascular risk.
Source
Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications
Katarzyna Zorena et al. · International Journal of Molecular Sciences · 2020
DOI 10.3390/ijms21103570
narrative_reviewCited 406×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Hypertrophic white adipocytes in obesity secrete pro-inflammatory cytokines (TNFα, IL-6, IL-1β) and adipokines (leptin, resistin) that induce local and systemic insulin resistance and chronic inflammation, leading to metabolic disorders like type 2 diabetes and cardiovascular disease.Good
- High-sensitivity C-reactive protein (hsCRP) levels are positively correlated with BMI and glycated hemoglobin, and elevated hsCRP (>3 mg/L) is an independent risk factor for the development of diabetic microangiopathy and cardiovascular disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →